Cargando…
Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector
PURPOSE: To evaluate the efficacy of recombinant adeno-associated virus (rAAV) vector expressing mouse angiostatin (Kringle domains 1 to 4) in reducing retinal vascular leakage in an experimental diabetic rat model. METHODS: rAAV-angiostatin was delivered by intravitreal injection to the right eyes...
Autores principales: | Shyong, Mong-Ping, Lee, Fenq-Lih, Kuo, Ping-Chang, Wu, Ai-Ching, Cheng, Huey-Chung, Chen, Show-Li, Tung, Tao-Hsin, Tsao, Yeou-Ping |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Molecular Vision
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533034/ https://www.ncbi.nlm.nih.gov/pubmed/17293777 |
Ejemplares similares
-
Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist
por: Tsai, Ming-Ling, et al.
Publicado: (2009) -
Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells
por: Cheng, Huey-Chuan, et al.
Publicado: (2008) -
Production and Titering of Recombinant Adeno-associated Viral Vectors
por: McClure, Christina, et al.
Publicado: (2011) -
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
por: Clément, Nathalie, et al.
Publicado: (2016) -
Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases
por: Li, Leyao, et al.
Publicado: (2023)